The HRT timing window: is 60 too late to start?

The HRT timing window

This is not medical advice — it is general information based on what you searched for that may help.

General information based on published sources and the symptoms you searched for. This isn't medical or legal advice, a diagnosis or a treatment plan. Please consult a doctor about your own symptoms. If your symptoms are severe or sudden, seek urgent care.

You'll see the same window referenced across our HRT guides: under age 60, or within 10 years of menopause onset. This section explains what that window actually means, and what changes if you're outside it.

What the window actually is

The Menopause Society describes a more favorable benefit-risk ratio for systemic HRT in women under 60 or within 10 years of menopause onset, without contraindications. Starting more than 10 years after menopause, or after age 60, is associated with higher absolute risks of coronary heart disease, stroke, blood clots, and dementia. NICE guidance adds a specific data point: dementia risk might increase with combined HRT if it's started at age 65 or over.

The "timing hypothesis," explained

This research idea goes a step further on cardiovascular risk specifically: HRT started within that same window (10 years of menopause, or before 60) may confer cardiovascular benefit, while starting later may increase cardiovascular risk. Importantly, a 2026 review on this exact question notes that outcomes vary by formulation, route, and individual factors, and that significant uncertainties persist in the research — this isn't a settled, simple rule. See our heart health after menopause guide for the broader cardiovascular picture, including why HRT still isn't used to prevent heart disease even within this favorable window.

It's a guideline, not a wall

None of this means HRT is impossible or forbidden after 60, or more than 10 years post-menopause. It means the benefit-risk calculation shifts, and starting later is a more individualized decision — exactly the kind of situation where NICE recommends involving someone with menopause expertise. See who HRT may suit, and who needs specialist advice for that fuller picture.

This timing framework is also part of the broader context behind the 2025–2026 FDA label changes — see the FDA boxed warning change, explained for how regulators and medical societies have debated this, and our Does It Work? evidence directory for non-hormonal options if timing rules HRT out for you.

Use our treatment conversation builder to prepare:

Where do I fall relative to the 10-years-or-under-60 window, and does that change the conversation about starting or continuing HRT?
If I'm outside that window, would a specialist consultation make sense before deciding?

Where are you right now?

Still tracking

Not sure if your symptoms fit? Start tracking your daily patterns.

Log and spot your patterns with the symptom checklist →

Ready to talk to a doctor

Have an upcoming appointment? Bring structured questions and your history.

Prepare your 10-minute doctor appointment questions →

Already on treatment

Evaluating your response or wondering what to adjust next?

Explore evidence-graded treatment and lifestyle options →

Questions people ask

Is 60 a hard cutoff for starting HRT?

No, it's a guideline, not a wall. The Menopause Society describes a more favorable benefit-risk ratio for starting under 60 or within 10 years of menopause onset, meaning risks are generally lower in that window, not that HRT becomes impossible or forbidden outside it. Starting later is a more individualized decision, usually best made with a menopause specialist.

What's the 'timing hypothesis'?

It's the research idea that when you start HRT relative to menopause changes its cardiovascular risk profile — starting earlier (within that same roughly-10-year or under-60 window) may be neutral or modestly favorable for heart health, while starting later is linked to more risk. It's an active area of research, not a fully settled question.

References

The 2022 Hormone Therapy Position Statement Advisory Panel. The 2022 hormone therapy position statement of The North American Menopause Society. Menopause (The North American Menopause Society, now The Menopause Society), 2022. Funding: Funded by donations to the NAMS Education & Research Fund; the statement reports no commercial support. Individual panel disclosures not yet reviewed..

Menopause: identification and management (NG23), Recommendations. National Institute for Health and Care Excellence (UK), 2026.

Khalifey HT, Mahereen R, Adwan R et al.. The impact of hormone replacement therapy on cardiovascular health in postmenopausal women: a narrative review. Frontiers in Reproductive Health, 2026.